Broadening Our Developmental Pipeline
Pipeline Chart, as of May 2017
BeyondSpring initiated a global Phase 3 pivotal trial evaluating Plinabulin for second-and third-line non-small cell lung cancer (NSCLC).
As we have further studied Plinabulin at the mechanistic and molecular levels, the Company has discovered additional applications, which allows us to positively anticipate the drug’s long-term potential and validate our initial belief that it has significant potential benefit beyond the initial target indication of NSCLC.
Given Plinabulin’s potential as a tumor micro-environment-targeting agent, we intend to initiate clinical trials in additional cancer indications:
- Immuno-oncology, with immune checkpoint inhibitors in NSCLC
- CNS malignancies including metastatic brain tumors
- KRAS positive mutant cancers
The Phase 2/3 Neutropenia registration trial targets solid tumor patients who have been previously treated with Docetaxel to prevent febrile Neutropenia.
BeyondSpring plans to initiate a Plinabulin immuno-oncology program to assess the safety and efficacy of Plinabulin in combination with PD-1 checkpoint inhibitor(s) to treat patients with advanced NSCLC.
The immune-oncology trial has begun enrolling patients as an investigator-initiated trial led by Dr. Lyudmila Bazhenova, M.D., professor of Clinical Medicine at Moores Cancer Center, University of California San Diego (UCSD).
Additionally, we have other promising immuno-oncology drug candidates under non-clinical development for various cancer indications: BPI-002, an oral small molecule activating T cells, and BPI-003, an oral novel small molecule IKK inhibitor.
In addition to developing the lead compound Plinabulin, which has the potential for treatment across a broad spectrum of cancers, we are also investigating areas to broaden our pipeline with multiple additional assets.
We are also in discussions to in-license product candidates.